In conclusion, using two whole body TET1 KO strategies, liver specific TET1 KO mice, and TET1 inhibitor treatment, we determined that suppressing TET1 ameliorated MASLD progression by inhibiting lipid metabolism through reducing fatty acid uptake. Here, TET1 is linked to metabolic dysfunction-associated steatotic liver disease.